Eyepoint, Inc. · NASDAQ:EYPT

Eyepoint — EyePoint Pharmaceuticals — Retina Society Annual Meeting 2024

12 slides from Eyepoint's conference presentation, September 2024

  1. Slide 1: 12-Month Results from the DAVIO 2 Trial

    12-MONTH RESULTS FROM THE DAVIO 2 TRIAL : A phase 2, multicenter study of a single injection of EYP-1901 (vorolanib intravitreal insert) vs aflibercept for previously-treated patients with wet age-related macular degeneration David A. Eichenbaum1 on behalf of DAVIO 2 investigators and coauthors Phil

  2. Slide 2: Presenter and Study Disclosures

    Presenter Disclosures 4DMT (I), Aerie/Alcon (I), Alexion (I), Alimera (C,S), Allegenesis (I), Allergan (C,S), Amaros (C,E), Annexon (C,I), Apellis (C,S), Astellas (I,C,S), Aviceda (I), Bausch & Lomb (C), Bayer (I,S), Boston Image Reading Center (E), Coherus (C), Complement Therapeutics (C), CorEvita

  3. Slide 3: EYP-1901 (DURAVYU): Vorolanib in Durasert E

    EYP-1901 (DURAVYUTM [vorolanib intravitreal insert]): Vorolanib in Durasert ETM EYP-1901 Vorolanib Durasert E Controlled release over a Potent receptor tyrosine kinase Bioerodible, sustained period of at least 6 months inhibitor (TKI): selectively inhibits all IVT drug delivery VEGF signaling No del

  4. Slide 4: DAVIO 2: Phase 2 trial of EYP-1901 vs aflibercept in previously-treated wet AMD

    DAVIO 2: Phase 2 trial of EYP-1901 vs aflibercept in previously-treated wet AMD Primary endpoint EYP-1901 dosing Blend W28 & W32 Key Inclusion & 161 patients W36 to D1 W4 W8 W12 W16 W20 W24 W28 W32 W56 Exclusion Criteria EYP-1901 2 mg low dose • Diagnosed with wAMD at (n = 53) any time EYP-1901 3 mg

  5. Slide 5: Baseline characteristics well-balanced across arms

    DAVIO 2 | 1 year Baseline characteristics well-balanced across arms Aflibercept 2 mg q8W EYP-1901 2 mg EYP-1901 3 mg (n = 54) (n = 50) (n = 52) Baseline Characteristics (N = 156) Age, mean years (range) 76 (52–93) 76 (61–93) 75 (56–89) Female, % 54% 64% 67% BCVA, mean ETDRS letter score (range) 73.4

  6. Slide 6: Nearly identical BCVA change with EYP-1901 and aflibercept at 12 months

    DAVIO 2 | 1 year Nearly identical BCVA change with EYP-1901 and aflibercept at 12 months EYP-1901 15 dosing Expected minimum duration of EYP-1901 in humans 10 Mean change vs BCVA change from baseline, aflibercept q8W mean ± SD ETDRS letters 5 Aflibercept q8W −0.5 0 EYP-1901 2 mg −0.1 +0.4 letters EY

  7. Slide 7: EYP-1901 demonstrated strong anatomic control with no sawtooth pattern

    DAVIO 2 | 1 year EYP-1901 demonstrated strong anatomic control with no sawtooth pattern EYP-1901 100 dosing 80 Expected minimum duration of EYP-1901 in humans 60 Mean change vs 40 aflibercept q8W CST change from baseline, 20 mean ± SD μm Aflibercept q8W 11.2 0 EYP-1901 2 mg 21.2 +10 μm -20 EYP-1901

  8. Slide 8: Eyes supplemental injection-free

    DAVIO 2 | 1 year EYP-1901–treated eyes were well-controlled, with similar proportions of patients meeting supplemental criteria as aflibercept q8W EYP-1901 dosing Expected minimum duration of EYP-1901 in humans 100% 87% Eyes supplemental injection–free 80% 68% 63% up to specified week, %a 60% 52% 63

  9. Slide 9: EYP-1901 substantially reduced treatment burden vs pre-trial treatment

    DAVIO 2 | 1 year EYP-1901 substantially reduced treatment burden vs pre-trial treatment Pre-trial treatment Study visit, months 12 11 10 9 8 7 6 5 4 3 2 1 0 1 2 3 4 5 6 7 8 9 10 11 12 47% injection free up to Month 12 83% reduction EYP-1901 Pre-trial anti-VEGF 2 mg vs pre-trial Scheduled aflibercept

  10. Slide 10: EYP-1901 demonstrated a favorable safety profile in DAVIO 2

    DAVIO 2 | 1 year EYP-1901 demonstrated a favorable safety profile in DAVIO 2 Key Safety Findings • No EYP-1901–related ocular SAEs or systemic SAEs • No insert migration into the anterior chamber • No cases of retinal occlusive vasculitis • No discontinuations related to EYP-1901 treatment • ≈97% of

  11. Slide 11: Summary

    Summary DAVIO 2 is the largest IVT TKI trial to date With one injection of EYP-1901, at 12 months: • EYP-1901 maintained stable visual acuity with strong anatomical control • Half of EYP-1901–treated eyes were supplement-free • About one-third of aflibercept q8W arm patients met criteria and EYP-190

  12. Slide 12: EYP-1901 in wet AMD: Phase 3 pivotal trial design

    EYP-1901 in wet AMD: Phase 3 pivotal trial design LUGANO & LUCIA: Patients with wet AMD, previously-treated or treatment-naïve Primary endpoint Blend W52 & W56 EYP-1901 dosing EYP-1901 dosing EYP-1901 dosing W60 to W84 to W96 D1 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 W56 W80 W76 W92 EOS E

EyePoint Pharmaceuticals — Retina Society Annual Meeting 2024 on 6ix